47.86
price up icon2.68%   1.25
pre-market  Pre-mercato:  48.60   0.74   +1.55%
loading
Precedente Chiudi:
$46.61
Aprire:
$46.67
Volume 24 ore:
425.23K
Relative Volume:
0.82
Capitalizzazione di mercato:
$2.92B
Reddito:
-
Utile/perdita netta:
$-145.21M
Rapporto P/E:
-20.81
EPS:
-2.3
Flusso di cassa netto:
$-140.12M
1 W Prestazione:
+1.03%
1M Prestazione:
+16.28%
6M Prestazione:
-10.66%
1 anno Prestazione:
+19.20%
Intervallo 1D:
Value
$46.32
$48.02
Intervallo di 1 settimana:
Value
$46.24
$48.72
Portata 52W:
Value
$31.42
$58.26

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name
Nome
Moonlake Immunotherapeutics
Name
Telefono
41 41 510 8022
Name
Indirizzo
DORFSTRASSE 29, ZUG
Name
Dipendente
100
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
MLTX's Discussions on Twitter

Confronta MLTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MLTX
Moonlake Immunotherapeutics
47.86 2.92B 0 -145.21M -140.12M -2.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-19 Aggiornamento Wolfe Research Peer Perform → Outperform
2025-03-18 Iniziato RBC Capital Mkts Outperform
2025-01-17 Aggiornamento Goldman Neutral → Buy
2024-11-05 Ripresa Wedbush Outperform
2024-08-26 Downgrade Wolfe Research Outperform → Peer Perform
2024-06-25 Iniziato Oppenheimer Outperform
2024-04-02 Iniziato Goldman Neutral
2024-02-15 Iniziato Wolfe Research Outperform
2023-12-08 Iniziato Citigroup Buy
2023-11-02 Iniziato Stifel Buy
2023-09-14 Downgrade Bryan Garnier Buy → Neutral
2023-08-31 Iniziato Needham Buy
2023-06-15 Iniziato Barclays Equal Weight
2023-05-01 Iniziato Guggenheim Buy
2023-03-22 Iniziato Wedbush Outperform
2023-03-09 Iniziato BTIG Research Buy
2023-02-14 Iniziato Cantor Fitzgerald Overweight
2023-02-02 Iniziato Bryan Garnier Buy
2022-11-11 Iniziato Jefferies Buy
2022-08-25 Iniziato SVB Leerink Outperform
2022-07-21 Iniziato H.C. Wainwright Buy
2022-07-07 Iniziato Cowen Outperform
Mostra tutto

Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie

pulisher
Jun 18, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Challenges - geneonline.com

Jun 18, 2025
pulisher
Jun 16, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Developments - geneonline.com

Jun 16, 2025
pulisher
Jun 15, 2025

Learn to Evaluate (MLTX) using the Charts - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 15, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Developments - geneonline.com

Jun 15, 2025
pulisher
Jun 13, 2025

MoonLake Immunotherapeutics’ SWOT analysis: nanobody firm’s stock poised for pivotal phase III data - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

IIH interview: Matthias Bodenstedt discusses MoonLake’s capital raising journey, the appeal of SLK and plans for the future - Investors in Healthcare

Jun 13, 2025
pulisher
Jun 13, 2025

MoonLake Immunotherapeutics: Strategic Positioning and Promising Clinical Developments Drive Buy Rating - TipRanks

Jun 13, 2025
pulisher
Jun 12, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Focus on Inflammatory Disease Treatments - geneonline.com

Jun 12, 2025
pulisher
Jun 10, 2025

MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Focus - geneonline.com

Jun 10, 2025
pulisher
Jun 09, 2025

MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics - TipRanks

Jun 09, 2025
pulisher
Jun 08, 2025

StockWatch: Report of $3B+ Merck Buyout Offer Propels MoonLake Stock Surge - Genetic Engineering and Biotechnology News

Jun 08, 2025
pulisher
Jun 07, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

MoonLake Immunotherapeutics Reportedly Exploring Potential Sale Amid Strategic Uncertainty - geneonline.com

Jun 07, 2025
pulisher
Jun 07, 2025

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

MoonLake Immunotherapeutics Elects Directors at AGM - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Merck held talks to buy biotech MoonLake for over $3 billion - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

These Stocks Moved the Most Today: Nvidia, Tesla, Dollar General, Credo, Ferguson, Moonlake, and More - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

MoonLake Immunotherapeutics Reportedly Exploring Potential Sale Amid Industry Speculation - geneonline.com

Jun 06, 2025
pulisher
Jun 05, 2025

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

MoonLake Immunotherapeutics Reportedly Considering Sale Amid Competitive Pharmaceutical Market Challenges - geneonline.com

Jun 05, 2025
pulisher
Jun 05, 2025

MoonLake Immunotherapeutics is for sale? This sounds like a cry for help - statnews.com

Jun 05, 2025
pulisher
Jun 04, 2025

Merck's Bold Proposal Sends MoonLake's Shares Climbing - Finimize

Jun 04, 2025
pulisher
Jun 04, 2025

Merck made $3B+ offer for MoonLake earlier this yearreport - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Two Biotechs That Could Get an M&A Boost - TheStreet Pro

Jun 04, 2025
pulisher
Jun 04, 2025

Merck & Co., Inc. (MRK) Held Talks Over $3 Billion Acquisition of Swiss Biotech Firm MoonLake - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Merck in Talks to Acquire MoonLake Immunotherapeutics for $3 Billion - geneonline.com

Jun 04, 2025
pulisher
Jun 04, 2025

MSD rumoured to be eyeing $3bn+ MoonLake takeover - pharmaphorum

Jun 04, 2025
pulisher
Jun 03, 2025

MoonLake Immunotherapeutics (MLTX) Surges 25% on Merck Acquisiti - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid - Investor's Business Daily

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest (MLTX) - Seeking Alpha

Jun 03, 2025
pulisher
Jun 03, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Shifts - geneonline.com

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake Immunotherapeutics Breaks Above 200-Day Moving AverageBullish for MLTX - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake's (MLTX) 'Outperform' Rating Reiterated by RBC Capital - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake takeover thesis reemerges after FT report, says Citi - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake Shares Jump On Potential Merck Acquisition Offer - Finimize

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake Immunotherapeutics: Strong Acquisition Interest and Promising Product Pipeline Drive Buy Rating - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

RBC Capital maintains outperform rating on Moonlake stock By Investing.com - Investing.com India

Jun 03, 2025
pulisher
Jun 03, 2025

RBC Capital maintains outperform rating on Moonlake stock - Investing.com

Jun 03, 2025

Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Moonlake Immunotherapeutics Azioni (MLTX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Sturge Simon
Director
Oct 04 '24
Sale
53.72
171,000
9,186,120
171,980
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):